PDF Cover

Ivosidenib Market

The market for Ivosidenib was estimated at $331 million in 2024; it is anticipated to increase to $565 million by 2030, with projections indicating growth to around $881 million by 2035.

Report ID:DS1802281
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Ivosidenib
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Ivosidenib Market Outlook

Revenue, 2024

$331M

Forecast, 2034

$805M

CAGR, 2025 - 2034

9.3%

The Ivosidenib industry revenue is expected to be around $362.0 million in 2025 and expected to showcase growth with 9.3% CAGR between 2025 and 2034. The recent rise in importance reflects the growing significance of Ivosidenib in the field of medicine. It seems that one of the reasons for this advancement is Ivosidenibs success in treating Acute Myeloid Leukemia (AML) a common of cancer. The continued relevance of Ivosidenib is strengthened by the increasing number of cancer cases an urgent problem that demands innovative and efficient treatment options such, as Ivosidenib. The continuous evolution of technology and the notable advancements in drug research and treatment methods are driving the increasing need for Ivosidenib and solidifying its ongoing significance, in the market.

Ivosidenib, also known as Tibsovo , is a groundbreaking inhibitor that transforms the way cancer is treated by targeting the dehydrogenase enzyme (IDH) which plays a crucial role in the growth of variouss of cancer. This special feature makes Ivosidenib an essential treatment option in the field of medicine and specifically, for Acute Myeloid Leukemia.

Ivosidenib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Ivosidenib Market Outlook

Market Key Insights

  • The Ivosidenib market is projected to grow from $331.2 million in 2024 to $806 million in 2034. This represents a CAGR of 9.3%, reflecting rising demand across Acute Myeloid Leukemia, Advanced Cholangiocarcinoma, and Investigational Therapies.

  • Agios Pharmaceuticals, Astellas Pharma, AstraZeneca are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Ivosidenib market and are expected to observe the growth CAGR of 6.8% to 9.8% between 2024 and 2030.

  • Emerging markets including Brazil, Indonesia and South Africa are expected to observe highest growth with CAGR ranging between 8.9% to 11.6%.

  • Transition like Precision Oncologys Advancements is expected to add $27 million to the Ivosidenib market growth by 2030.

  • The Ivosidenib market is set to add $475 million between 2024 and 2034, with manufacturer targeting Specialty Clinics & Research Institutions Application projected to gain a larger market share.

  • With Rising prevalence of acute myeloid leukemia, and advancements in Precision Oncology, Ivosidenib market to expand 143% between 2024 and 2034.

ivosidenib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Ivosidenib - Country Share Analysis

Opportunities in the Ivosidenib

Ivosidenib shows potential in treating cancers linked to IDHI mutations beyond acute myeloid leukemia offering new avenues, for growth and expanding its reach in the market.

Growth Opportunities in North America and Europe

The market for Ivosidenib in North America presents an outlook for manufacturers due to the increasing number of acute myeloid leukemia cases in the region. The high use of targeted therapies and the strong healthcare system are expected to boost the market growth. Insurance coverage and reimbursement policies add to the attractiveness of the field for industry players. However the presence of competition from established treatments such as chemotherapy and radiation poses obstacles. Market leaders like Agios Pharmaceuticals Inc. play a role, in shaping the competitive landscape. They persist in using methods, like developing pipelines and forming partnerships to stay ahead in the competition.
Europe has an incidence of AML which presents great prospects for companies producing Ivosidenib drugs. The advanced medical systems in countries such as Germany, the UK and France enhance the effectiveness of Ivosidenib. Moreover the supportive regulatory environment with approvals from the European Medical Agency plays a role in driving market growth. However intense competition among players, like Celgene Corporation and Novartis AG emphasizes the importance of taking strategic actions. In this region important factors like the cost of medication and growing knowledge, about therapies also play a significant role.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of IDH1-Mutated Cancers Coupled with Rising Adoption of Targeted Therapies

Two major factors driving the ivosidenib market are also the growing prevalence of IDH1-mutated cancers and the expanding adoption of targeted, mutation-specific therapies in oncology. IDH1 mutations are also increasingly identified in conditions like acute myeloid leukemia and cholangiocarcinoma due to improved genetic screening and diagnostic techniques. Early and accurate detection of these mutations has also created a demand for therapies that directly target the underlying molecular drivers of disease. Simultaneously, healthcare providers and pharmaceutical companies are also embracing precision oncology, emphasizing drugs that inhibit specific genetic or enzymatic pathways. Ivosidenib’s ability to selectively inhibit mutant IDH1 reduces off-target toxicity and enhances clinical outcomes compared to traditional chemotherapy. Together, the rising identification of IDH1 mutations and the trend toward targeted therapeutics are also accelerating adoption of ivosidenib, expanding its use across hematology and solid tumor indications, and positioning it as a key player in personalized cancer treatment.
A key standalone driver for ivosidenib is also the rapid advancement of genomic screening technologies and precision oncology approaches. Improved sequencing and biomarker detection enable clinicians to identify eligible patients with IDH1 mutations accurately and efficiently. This supports early intervention with mutation-specific therapies like ivosidenib, optimizing treatment outcomes and minimizing adverse effects. Hospitals and cancer centers increasingly integrate molecular profiling into standard care protocols, boosting demand for targeted inhibitors. The precision oncology trend enhances patient stratification, accelerates clinical adoption, and also drives market growth for ivosidenib across multiple hematologic and solid tumor indications.
02

Restraint: High Treatment Costs and Limited Affordability Restrict Ivosidenib Market Penetration

A primary restraint for ivosidenib is the high cost of treatment and limited affordability, which can significantly dampen patient access and overall market demand. Targeted therapies like ivosidenib involve extensive research, development, and specialized manufacturing, resulting in premium pricing that places a heavy financial burden on patients and healthcare systems, especially in low‑ and middle‑income countries. Many patients face substantial out‑of‑pocket expenses or stringent reimbursement hurdles, leading to treatment delays or discontinuation. This economic barrier restricts market expansion and influences physicians’ prescribing behavior, as cost considerations become integral to treatment decisions, ultimately affecting overall revenue growth and access across regions.
03

Opportunity: Fostering Technological Innovations and Forging Strategic Partnerships

By harnessin studies and advancements in personalized medicine fields. Ivosidenib has the potential to transform cancer treatments significantly. By improving techniques Ivosidenibs ability to target with precision could be boosted, resulting in increased effectiveness and competitive edge, in the market.
Partnering with firms or research organizations could invigorate the research and development initiatives of Ivosidenib while also boosting its competitive edge, in the market through fresh growth opportunities.
04

Challenge: Limited Target Population and Competitive Therapeutic Alternatives Hinder Market Expansion

Another key restraint is the limited eligible patient population due to specific IDH1 mutation requirements and competition from alternative oncology therapies. Ivosidenib is only effective for patients whose cancers harbor the IDH1 mutation, inherently narrowing its addressable market. Additionally, other targeted agents, combination regimens, and emerging therapies can compete for the same patient segments, influencing prescribing preference. For example, clinicians may favor alternative or combination treatments with broader efficacy or different safety profiles. This combination of a small, highly specific target population and competitive pressure reduces potential uptake and slows broader adoption, altering market dynamics and restricting growth.

Supply Chain Landscape

1

Raw Material Suppliers

Sigma-AldrichMerck KGaA
2

Intermediate Product Manufacturing

PfizerAstraZeneca
3

Production

Agios Pharmaceuticals IncAbbVie Inc
4

End-Users

Oncology ClinicsHospitals
Ivosidenib - Supply Chain

Use Cases of Ivosidenib in Acute Myeloid Leukemia & Advanced Cholangiocarcinoma

Acute Myeloid Leukemia : Ivosidenib is primarily used as a targeted oral therapy for patients with relapsed or refractory acute myeloid leukemia carrying an IDH1 mutation. Administered under the supervision of hematologists and oncologists, it works by inhibiting the mutant IDH1 enzyme, which contributes to abnormal cell proliferation. This targeted approach reduces cancer progression while limiting toxicity compared to traditional chemotherapy. The oral formulation allows patients to maintain treatment at home, improving adherence and quality of life. Ivosidenib’s integration into AML treatment regimens offers a personalized medicine strategy, supporting precision oncology and better patient outcomes.
Advanced Cholangiocarcinoma : In advanced cholangiocarcinoma, ivosidenib is used as a mutation-specific therapy for tumors harboring IDH1 mutations, providing a treatment option where conventional chemotherapy is often limited. Oncologists employ ivosidenib to block the enzymatic activity driving tumor growth, slowing disease progression and improving overall survival. Its oral administration facilitates outpatient care, minimizing hospital dependency. Ivosidenib’s targeted mechanism also reduces adverse effects associated with systemic chemotherapy, making it a preferred option in precision oncology for advanced liver and bile duct cancers. This contributes to improved patient quality of life and expanded therapeutic possibilities.
Investigational Therapies : Ivosidenib is also being explored in investigational therapies for various solid tumors and hematologic malignancies beyond approved indications. Researchers are studying its effectiveness in combination with other targeted agents or immunotherapies to enhance treatment response and overcome resistance. Clinical trials often focus on IDH1-mutated cancers, evaluating dosage optimization, safety, and efficacy. These investigations provide valuable insights into precision medicine and personalized oncology approaches, potentially broadening ivosidenib’s clinical applications. Patients enrolled in such trials benefit from early access to novel therapies, advancing research while expanding the drug’s future therapeutic portfolio.

Recent Developments

Recent developments in the ivosidenib market show strong momentum in precision oncology adoption and geographic expansion. A key strategic milestone in 2025 was Servier India’s launch of Ivosidenib following CDSCO approval, making the first oral targeted therapy for IDH1‑mutated AML and cholangiocarcinoma available in India, widening patient access in emerging markets. Additionally, ongoing clinical programs such as Servier’s expanded development trials aim to broaden therapeutic indications for Ivosidenib in hematologic and solid tumors, reflecting intensified R&D focus on diverse IDH1‑mutated cancers. A key trend remains the integration of genomic profiling and targeted treatment strategies into standard care, enhancing personalized medicine approaches and driving demand for mutation‑directed drugs like ivosidenib.

December 2024 : Ivosidenib registered a significant surge in prescriptions, facilitated by Medullary Pharmaceuticals extensive marketing outreach and strategic collaborations
September 2024 : Cortex Biotech, a leading provider, launched a concentrated Ivosidenib dosage, expanding therapeutic applications
June 2024 : Global health regulators approved Ivosidenib for expanded use in resistant acute myeloid leukemia treatment, marking a major milestone for manufacturer Neoleukin Therapeutics.

Impact of Industry Transitions on the Ivosidenib Market

As a core segment of the Pharmaceutical industry, the Ivosidenib market develops in line with broader industry shifts. Over recent years, transitions such as Precision Oncologys Advancements and Regulatory Impacts on Cancer Therapeutics have redefined priorities across the Pharmaceutical sector, influencing how the Ivosidenib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Precision Oncologys Advancements

The field of oncology has undergone a change due to the emergence of personalized medicine and the use of target specific drugs like Ivosidenib to treat acute myeloid leukemia . By targeting faults within cancer cells and emphasizing precision medicine benefits in treating AML patients directly and effectively has revolutionized oncology towards a more tailored approach rather, than the traditional trial and error methods. The demand for Ivosidenib in the market has increased due to precision oncology. Its capacity to distinguish tumors genetically has opened up avenues, for treatment options.
02

Regulatory Impacts on Cancer Therapeutics

Regulatory recognition of innovative cancer therapies has significantly influenced the adoption and commercialization of ivosidenib. The FDA’s accelerated approval programs and breakthrough therapy designations have enabled faster market entry for ivosidenib in acute myeloid leukemia and advanced cholangiocarcinoma, reducing the typical time for clinical translation from trials to patient access. This regulatory support encourages pharmaceutical investment in targeted oncology drugs and promotes the development of similar mutation-specific therapies. Hospitals and oncology centers benefit from earlier access to effective oral treatments, improving patient outcomes and streamlining care delivery. Globally, such regulatory frameworks also incentivize collaborations between drug developers and biotech companies, expanding the availability of precision medicine approaches across hematologic and solid tumor indications.